JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Membranoprolferative glomerulonephritis - mechanisms and treatment.

Membranoproliferative glomerulonephritis (MPGN) is a histologic pattern of glomerular damage with many etiologies. In the past, it was divided into secondary and primary, or idiopathic forms. In turn, the idiopathic forms were labeled MPGN types I, II, and III based on ultrastructural localization of the electron-dense 'deposits'. A recent major change in classification relies on the presence of immunoglobulins and complement to determine etiologies that are more in line with the pathogenesis of the disease. Idiopathic MPGN II, now called dense deposit disease and C3 glomerulonephritis, are now recognized as diseases of the alternate complement pathway. They are caused by a variety of alternate complement pathway defects including genetic forms and those due to autoantibodies that either activate accelerators of the pathway or block inhibitors of the cascade. These patients need to be evaluated in a different fashion and receive different therapy than those patients with MPGN forms associated with immunoglobulin deposition.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app